Oruka Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Oruka Therapeutics, Inc. (Nasdaq: ORKA) is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. The company's core strategy is a classic 'best-in-class' approach, utilizing validated biology and optimizing product profiles through advanced antibody engineering (including half-life extension) to support less-frequent maintenance dosing (such as once or twice-yearly) while preserving high efficacy. Oruka's lead program, ORKA-001, is a subcutaneously administered, half-life extended monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23p19). Its co-lead program, ORKA-002, targets interleukin-17A and interleukin-17F (IL-17A/F). The company was formed via a reverse merger with ARCA biopharma, Inc. in September 2024.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, through Phase 2 clinical trials (EVERLAST-A and EVERLAST-B) to establish a potential once-yearly dosing regimen for moderate-to-severe plaque psoriasis.
Expected impact: Aims to set a new standard of care in plaque psoriasis by achieving high rates of complete disease clearance (PASI 100) with highly infrequent dosing.
Developing ORKA-002, a novel half-life extended IL-17A/F monoclonal antibody, for the treatment of plaque psoriasis and hidradenitis suppurativa (HS).
Expected impact: Provides a highly complementary mechanism of action to ORKA-001, targeting twice-yearly dosing in psoriasis and quarterly dosing in HS.
Global exclusive collaboration and license agreement with Halozyme to apply its Hypercon microparticle technology to ORKA-001 and up to one additional target.
Expected impact: Enables hyperconcentration of ORKA-001, reducing injection volume to support more convenient, patient-friendly subcutaneous administration.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
A transformative reverse merger that transitioned private Oruka into a publicly traded entity on the Nasdaq Global Market under the ticker 'ORKA'. The transaction was supported by a concurrent $275 million private placement (PIPE) to fund the development of Oruka's immunology and dermatology pipeline.
Financial impact: Provided the public corporate vehicle and initial capital to advance lead assets ORKA-001 and ORKA-002 into clinical trials.
Strategic Partnerships
Oruka was founded based on assets generated by Paragon. Oruka holds exclusive worldwide rights to develop, manufacture, and commercialize its lead programs (including ORKA-001 and ORKA-002) engineered by Paragon.
Terms: Oruka is obligated to pay Paragon development, regulatory, and clinical milestones (e.g., up to $22.0 million for the first IL-23 product), as well as low single-digit percentage royalties on net sales.
Provides Oruka with exclusive rights to use Halozyme's Hypercon microparticle technology for ORKA-001 in psoriatic disease and up to one additional target.
Terms: Oruka will make an upfront payment and potential future milestone payments to Halozyme, and Halozyme is eligible to receive mid-single-digit royalties on net sales of products developed using the technology.